• American Association for Cancer Research: Glactone Pharma to present data on the effect of new compound on anti-androgen resistant prostate cancer cells
  • PULS önskar alla en glad påsk!

Sweden's leading private life science incubator

PULS turns life science projects into attractive business opportunities for the life science industry. Each project is based on a well-defined medical need. PULS secures long-term financing and world-class scientific and industrial expertise through joint ownership with innovators. Our track record validates all aspects of our business model – a model that serves both innovators and investors well. Try us!

News from PULS

18 March, 2015

Valberedningens förslag till ny styrelse inför årsstämman 2015: LIDDS AB meddelar idag valberedningens förslag till ny styrelse inför årsstämman 2015

Utifrån de krav som kommer att ställas på styrelsen till följd av bolagets läge och framtida inriktning har valberedningen diskuterat styrelsens storlek och sammansättning, vad avser till exempel branscherfarenhet, medicinsk kompetens, internationell erfarenhet och mångfald. Att styrelsen skall bestå av fem ordinarie styrelseledamöter och inga suppleanter.

12 March, 2015

American Association for Cancer Research: Glactone Pharma to present data on the effect of new compound on anti-androgen resistant prostate cancer cells

Glactone Pharma will be presenting new exciting data at the annual meeting for AACR, on April 19, that demonstrate that the STAT3 inhibitor GPA500 suppresses the growth of prostate cancer cells resistant to second-generation anti-androgens. With GPA500 as a lead, Glactone Pharma has developed novel proprietary STAT3 inhibitors with improved drug like properties.

Find out more
Innovators
Do you have an idea?
Partners
Do you have the knowledge?
Investors
Do you have the experience?

© 2012-2015 P.U.L.S. AB | Kullagatan 8, 252 20 Helsingborg, Sweden | All rights reserved.